Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2017

View Archived Issues

Phase II data support use of ridinilazole as treatment for CDI

Ligand reports topline results from phase II trial of LGD-6972

FDA gives rare pediatric disease designation to Global Blood Therapeutics' GBT-440

GLP-1R agonist reduces intracranial pressure in a rat model of hydrocephalus

Retrophin enters collaboration to find therapeutics for NGLY1 deficiency

Cocrystal Pharma enters drug discovery collaboration with HitGen and InterX

Insmed reports topline data from CONVERT study of ALIS

Eagle Pharmaceuticals evaluates neuroprotective effects of Ryanodex in rodents

FDA approves Dotarem for use in children under 2 years of age

FDA, EMA grant orphan drug designation to QRX-421 for Usher syndrome

Grant supports IBBR's development of multispecific antibody as therapeutic for HIV

Prodrug improves cell targeting of glutaminase antagonist for hematological malignancies

Pulmatrix receives award to support development of PUR-1900

MacroGenics advances two bispecific DART product candidates

MEI licenses rights to voruciclib from Presage

Adipolin identified as a biomarker of coronary artery disease

Eiger BioPharmaceuticals obtains FDA orphan drug designation for HDV treatment

BioNTech enters patent licensing agreement with Cellscript for modified mRNA technology

Farmar Licensing discloses novel recombinant beta2 glycoprotein 1 peptides

Enzyvant Therapeutics' RVT-802 awarded FDA rare pediatric disease designation

University of Primorska, Institute of Oncology Ljubljana patent IL-12 cancer gene therapy

U.S. Department of Health & Human Services creates new nucleic acids encoding arginase

Biocon partners with JDRF for Insulin Tregopil trial in type 1 diabetes

Novel antibacterial compounds identified at Redx Pharma

Chrysalis presents new lysine-specific demethylase 5B inhibitors

Bioverativ and Bicycle form research collaboration in hemophilia and sickle cell disease

Avadel enters license agreement for U.S. and Canadian rights to Noctiva

Ortho Dermatologics submits NDA for IDP-118 for plaque psoriasis

Janssen discovers prostanoid EP3 receptor antagonists with promising drug characteristics